Journal of Clinical Oncology, Vol 12, 596-600, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis

PJ Hesketh, WH Harvey, WG Harker, TM Beck, T Ryan, LJ Bricker, JA Kish, WK Murphy, JD Hainsworth and B Haley
Boston University Medical Center, MA.

PURPOSE: This study compares the efficacy and safety of ondansetron alone with that of ondansetron plus dexamethasone in the prevention of emesis induced by high-dose cisplatin (> or = 100 mg/m2). PATIENTS AND METHODS: This multicenter study used a randomized, double-blind, parallel-group design. Chemotherapy-naive patients were randomized to receive intravenous (IV) ondansetron (Zofran, Cerenex Pharmaceuticals, Research Triangle Park, NC) 0.15 mg/kg for three doses every 4 hours beginning 30 minutes before cisplatin administration either alone or in combination with dexamethasone 20 mg administered 45 minutes before cisplatin. Cisplatin (> or = 100 mg/m2) was administered as a single infusion (< or = 3 hours). Patients were monitored for emetic episodes (EEs), adverse events, and laboratory safety parameters for 24 hours after cisplatin administration. RESULTS: A total of 275 patients were enrolled. Of these, 245 were assessable for efficacy. Patients who received ondansetron plus dexamethasone had a higher complete antiemetic response rate (61% v 46%, P = .02) and less nausea (posttreatment visual analog scale mean 18.2 v 32.8, P < .001) than did those who received ondansetron alone. The time to the first EE was longer for patients in the group that received ondansetron plus dexamethasone (P = .005). Headache (12%), diarrhea (2%), and abdominal colic (1%) were the most common antiemetic-related adverse events reported. The incidence of adverse events was similar between the treatment groups. CONCLUSION: IV ondansetron in combination with dexamethasone is safe and more effective than ondansetron alone in the prevention of emesis induced by high-dose cisplatin.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Maemondo, N. Masuda, I. Sekine, K. Kubota, Y. Segawa, M. Shibuya, F. Imamura, N. Katakami, T. Hida, S. Takeo, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy Ann. Onc., November 1, 2009; 20(11): 1860 - 1866. [Abstract] [Full Text] [PDF]

				P. J. Hesketh Chemotherapy-Induced Nausea and Vomiting N. Engl. J. Med., June 5, 2008; 358(23): 2482 - 2494. [Full Text] [PDF]

				M. Hamadani, L. Chaudhary, F. T. Awan, J. K. Khan, K. Kojouri, H. Ozer, and A. Tfayli Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist? Journal of Oncology Pharmacy Practice, June 1, 2007; 13(2): 69 - 75. [Abstract] [PDF]

				M. Aapro, S. Grunberg, G. Manikhas, G Olivares, T Suarez, S. Tjulandin, L. Bertoli, F Yunus, B Morrica, F Lordick, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Ann. Onc., September 1, 2006; 17(9): 1441 - 1449. [Abstract] [Full Text] [PDF]

				M. C. Rosenhagen, C. Soti, U. Schmidt, G. M. Wochnik, F. U. Hartl, F. Holsboer, J. C. Young, and T. Rein The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation Mol. Endocrinol., October 1, 2003; 17(10): 1991 - 2001. [Abstract] [Full Text] [PDF]

				R. H. Rosen Management of Chemotherapy-Induced Nausea and Vomiting Journal of Pharmacy Practice, February 1, 2002; 15(1): 32 - 41. [Abstract] [PDF]

				K. S. Weiss Anaphylactic Reaction to Ondansetron Arch Intern Med, October 8, 2001; 161(18): 2263 - 2263. [Full Text] [PDF]

				T. Sigsgaard, J. Herrstedt, J. Handberg, M. Kjar, and P. Dombernowsky Ondansetron Plus Metopimazine Compared With Ondansetron Plus Metopimazine Plus Prednisolone as Antiemetic Prophylaxis in Patients Receiving Multiple Cycles of Moderately Emetogenic Chemotherapy J. Clin. Oncol., April 1, 2001; 19(7): 2091 - 2097. [Abstract] [Full Text] [PDF]

				D. Campos, J. R. Pereira, R. R. Reinhardt, C. Carracedo, S. Poli, C. Vogel, J. Martinez-Cedillo, A. Erazo, J. Wittreich, L.-O. Eriksson, et al. Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone J. Clin. Oncol., March 15, 2001; 19(6): 1759 - 1767. [Abstract] [Full Text] [PDF]

				J. P. A. Ioannidis, P. J. Hesketh, and J. Lau Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence J. Clin. Oncol., October 19, 2000; 18(19): 3409 - 3422. [Abstract] [Full Text] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]

				R. M. Navari, R. R. Reinhardt, R. J. Gralla, M. G. Kris, P. J. Hesketh, A. Khojasteh, H. Kindler, T. H. Grote, K. Pendergrass, S. M. Grunberg, et al. Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1-Receptor Antagonist N. Engl. J. Med., January 21, 1999; 340(3): 190 - 195. [Abstract] [Full Text] [PDF]

				P. J. Hesketh, R. J. Gralla, R. T. Webb, W. Ueno, S. DelPrete, M. E. Bachinsky, N. L. Dirlam, C. B. Stack, and S. L. Silberman Randomized Phase II Study of the Neurokinin 1 Receptor Antagonist CJ-11,974 in the Control of Cisplatin-Induced Emesis J. Clin. Oncol., January 1, 1999; 17(1): 338 - 338. [Abstract] [Full Text] [PDF]

				J. I. Spector, E. P. Lester, E. M. Chevlen, D. Sciortino, J. H. Harvey, W. Whaley, S. Madajewicz, R. Isaacs, H. D. Homesley, S. Yee, et al. A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy Oncologist, December 1, 1998; 3(6): 432 - 438. [Abstract] [Full Text]